1. < Dermatology

Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature

By sjmartinez • January 2, 2025

Barghi A, Noveir SD, Mainwaring W, Milani-Nejad N, Bernet L. Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: A case report and review of the literature. Int J Dermatol. 2024 Dec 30. doi: 10.1111/ijd.17626. Epub ahead of print. PMID: 39739856.

Tags: bullous pemphigoid, Dermatology, DGSOM Student, Dupilumab, eosinophilic annular erythema, immune checkpoint inhibitor, pembrolizumab, Publications

Related Posts

Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review

Kakani P, Davis J. Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review. Skinmed. 2024 Dec 31;22(6):422-426. PMID: 39748573.

An evaluation framework for clinical use of large language models in patient interaction tasks

Johri S, Jeong J, Tran BA, Schlessinger DI, Wongvibulsin S, Barnes LA, Zhou HY, Cai ZR, Van Allen EM, Kim D, Daneshjou R, Rajpurkar P.[...]

Efficacy and Safety of Tildrakizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis of the Scalp: Week 52 Results From a Phase 3b, Randomized, Double-Blind, Placebo-Controlled Trial

Sofen HL, Gebauer K, Spelman L, Yamauchi PS, Yao SL, Nishandar T, Kopeloff I, Crane M, Gogineni R, Kothekar M, Bagel J. Efficacy and Safety[...]